Precision therapeutics for major unmet medical needs
About Us
Changing the way we treat disease
We have a decade of data informing our strategy including patient responder analyses, rigorous dose modeling and flawless clinical execution. As a result, our therapeutic candidates have maximum potential for patient impact. Find out more about the SPRING trial for P. gingivalis positive Alzheimer's disease.
News & Events
Lighthouse Pharmaceuticals Reports New Evidence that Gingipain Inhibition Benefits Neuropsychiatric Symptoms and Reduces Caregiver Distress in P. gingivalis-Positive Alzheimer's Disease at AAIC 2026 More here
​
Lighthouse Pharmaceuticals Closes $12 Million Series A Financing Led by Double Point Ventures
Proceeds from the financing will support advancement of Lighthouse’s lead program, LHP588, in patients with P. gingivalis-positive mild to moderate Alzheimer’s disease and continued pipeline expansion. More here
​
Lighthouse Pharmaceuticals to Present Phase 2 SPRING Trial of LHP588, a Next-Generation Gingipain Inhibitor for the Treatment of P. gingivalis-Positive Alzheimer’s Disease, at CTAD 2025
​
Lighthouse Pharmaceuticals Relocates Headquarters to the Buck Institute for Research on Aging
​
Phibro Animal Health Corporation Announces Licensing Agreement with Lighthouse Pharmaceuticals, Inc. for Innovative Periodontal Health Asset for Dogs
​
Lighthouse Pharmaceuticals Receives $49.2 Million Grant from NIA to Advance Phase 2 Study of LHP588 for P. gingivalis-Positive Alzheimer’s Disease
Groundbreaking Clinical Trial to Enroll 300 Patients in Double-Blind, Placebo-Controlled Study of Lysine-Gingipain Inhibitor
